Antibody Engineering for Nuclear Imaging and Radioimmunotherapy

The Journal of Nuclear Medicine

article

Cindy Rodriguez¹  Samantha Delaney¹  Samantha M. Sarrett¹  Outi M. Keinänen¹  Brian M. Zeglis¹ 

[1] Department of Chemistry, Hunter College, City University of New York;Department of Radiology, Memorial Sloan Kettering Cancer Center;Department of Chemistry, University of Helsinki;Ph.D. Program in Chemistry, Graduate Center of City University of New York;Ph.D. Program in Biochemistry, Graduate Center of City University of New York;Department of Radiology, Weill Cornell Medical College

关键词: PET;    radioimmunotherapy;    antibody;    antibody fragment;    antibody engineering;    Fc receptor;   

DOI  :  10.2967/jnumed.122.263861

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

Radiolabeled antibodies have become indispensable tools in nuclear medicine. However, the natural roles of antibodies within the immune system mean that they have several intrinsic limitations as a platform for radiopharmaceuticals. In recent years, the field has increasingly turned to antibody engineering to circumvent these issues while retaining the manifold benefits of the immunoglobulin framework. In this “Focus on Molecular Imaging” review, we cover recent advances in the application of antibody engineering to immunoPET, immunoSPECT, and radioimmunotherapy. Specifically, we address how antibody engineering has been used to improve radioimmunoconjugates on four fronts: optimizing pharmacokinetics, facilitating site-specific bioconjugation, modulating Fc interactions, and creating bispecific constructs.

【 授权许可】

CC BY